ArticleEuropean archives of psychiatry and clinical neuroscience2026
Association between antidepressant use and the risk of type 2 diabetes: a multi-stage Mendelian randomization study.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDepression is a highly prevalent condition, and antidepressants are widely used to manage its symptoms. However, concerns have emerged regarding a potential causal relationship between antidepressant use and the development of type 2 diabetes (T2D). Understanding these potential relationships may provide insights into the metabolic heterogeneity of antidepressant medications.
methodsThis study utilized two-sample Mendelian randomization (MR) to investigate the potential causal effects of genetic liability to antidepressant use on the risk of T2D. Genome-wide association study (GWAS) summary datasets were employed, covering various classes of antidepressants (120,446 cases and 94,450 controls) and T2D (discovery set: 80,154 cases and 853,816 controls; validation set: 71,728 cases and 369,007 controls). MR analysis was performed to estimate odds ratios (ORs) and assess the causal associations between antidepressant use and T2D.
resultsThe MR analysis identified significant causal associations between liability to use of specific antidepressants, including citalopram and sertraline, and T2D susceptibility. Validation using meta-analysis data of T2D confirmed these findings, with citalopram (OR 1.05, 95% CI 1.01-1.09, P = 0.018) and sertraline (OR 1.02, 95% CI 1.01-1.04, P = 1.22E-03) demonstrating significant associations. Additionally, the use of amitriptyline showed a suggestive association with T2D susceptibility (OR 1.04, 95% CI 1.01-1.08, P = 0.018).
conclusionsThis study provides genetic evidence suggesting medication-specific associations between antidepressant use liability and T2D susceptibility. Although the observed effect sizes were modest, these results highlight that the metabolic effects of individual antidepressants may vary, thus, warranting further studies to determine the clinical relevance of our findings.
Identifiers
42667416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.